Sacral neuromodulation and botulinum toxin for overactive neurogenic bladder in children

被引:0
|
作者
Aubert, D. [1 ]
Galli, G. [1 ]
Ramella, B. [1 ]
Moro-Enemuwe, A. [1 ]
Fotso-Kamden, A. [1 ]
机构
[1] CHU St Jacques, Serv Chrurg Pediat, F-25000 Besancon, France
来源
PELVI-PERINEOLOGIE | 2007年 / 2卷 / 03期
关键词
paediatric urology; neurogenic bladder; sacral neuromodulation; botulinum toxin;
D O I
10.1007/s11608-007-0137-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Overactive bladder is a major cause of urinary tract damage in children with congenital neurogenic bladder. Anticholinergics and bladder augmentation are the standard treatments. S3 sacral neuromodulation (InterStim (R)) and botulinum toxin injection (Botox (R) 12 mg/kg or Dysport (R)) into the detrusor muscle have recently been shown to be effective in adults. In children, the use of these treatments is still uncommon but the first results are as promising as those in adults and no adverse effects have been reported. In France, there is a need for additionnal randomized, multicenter trials to confirm the benefits of these two procedures in paediatric urology.
引用
收藏
页码:244 / 248
页数:5
相关论文
共 50 条
  • [31] Botulinum toxin for overactive bladder
    Ziegelmueller, B. K.
    Sommer, A.
    Bauer, R. M.
    UROLOGE, 2020, 59 (08): : 963 - 972
  • [32] Pediatric Overactive Bladder and the Role of Sacral Neuromodulation
    Johnston A.W.
    Whittam B.M.
    Current Treatment Options in Pediatrics, 2022, 8 (4) : 412 - 422
  • [33] Sacral neuromodulation for the treatment of overactive bladder in men
    Sutherland S.E.
    Mindrup S.R.
    Siegel S.W.
    Current Bladder Dysfunction Reports, 2007, 2 (2) : 117 - 123
  • [34] Botulinum toxin in the treatment of neurogenic bladder in adults and children
    Schurch, Brigitte
    Schulte-Baukloh, Heinrich
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (11) : 679 - 684
  • [35] Botulinum-A toxin in the treatment of neurogenic bladder in children
    Schulte-Baukloh, H
    Knispel, HH
    Michael, T
    PEDIATRICS, 2002, 110 (02) : 420 - 421
  • [36] Re: Cost-Effectiveness Analysis of Sacral Neuromodulation and Botulinum Toxin A Treatment for Patients With Idiopathic Overactive Bladder Editorial Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2012, 187 (06): : 2157 - 2158
  • [37] Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients
    Reekmans, Mathias
    Janssen, Janine M. W.
    Vrijens, Desiree M. J.
    Smits, Martijn A. C.
    van Koeveringe, Gommert A.
    Van Kerrebroeck, Philip E. V. A.
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 (05) : 1120 - 1125
  • [38] A MARKOV MODEL COMPARING SACRAL NEUROMODULATION AND BOTULINUM TOXIN-A FOR MEDICARE PATIENTS WITH IDIOPATHIC OVERACTIVE BLADDER REFRACTORY TO CONSERVATIVE CARE
    Ganz, M.
    Clemens, J. Q.
    Anger, J.
    Denevich, S.
    Shah, D.
    Carlson, A.
    Wittek, M. R.
    Pashos, C.
    VALUE IN HEALTH, 2011, 14 (03) : A76 - A77
  • [39] The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple, Christopher
    De Ridder, Dirk
    BJU INTERNATIONAL, 2009, 104 (09) : 1188 - 1190
  • [40] Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System
    Maria Paola Bertapelle
    Mario Vottero
    Giulio Del Popolo
    Marco Mencarini
    Edoardo Ostardo
    Michele Spinelli
    Antonella Giannantoni
    Anna D’Ausilio
    World Journal of Urology, 2015, 33 : 1109 - 1117